Radius Health Inc Stock Price Could Go Up After Today’s Bullish Options Activity

 Radius Health Inc Stock Price Could Go Up After Today's Bullish Options Activity

In today’s session Radius Health Inc (RDUS) registered an unusually high (568) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious RDUS increase. With 568 contracts traded and 16784 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: RDUS161021C00070000 closed last at: $0.85 or 142.9% up. About 44,437 shares traded hands. Radius Health Inc (NASDAQ:RDUS) has risen 50.27% since March 10, 2016 and is uptrending. It has outperformed by 42.75% the S&P500.

Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on November, 3. They expect $-1.04 earnings per share, down 52.94% or $0.36 from last year’s $-0.68 per share. After $-1.01 actual earnings per share reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 2.97% negative EPS growth.

Radius Health Inc (NASDAQ:RDUS) Ratings Coverage

Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Radius Health Inc (NASDAQ:RDUS) earned “Buy” rating by Canaccord Genuity on Thursday, September 24. The firm has “Buy” rating given on Wednesday, September 21 by H.C. Wainwright. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. The firm earned “Overweight” rating on Friday, October 2 by JP Morgan. The rating was reinitiated by Cowen & Co on Friday, May 6 with “Outperform”. The stock has “Buy” rating given by H.C. Wainwright on Monday, May 23. As per Friday, August 14, the company rating was initiated by Deutsche Bank. The firm earned “Hold” rating on Wednesday, February 24 by Jefferies.

According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.03, from 1.29 in 2016Q1. The ratio improved, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
Franklin Incorporated holds 464,200 shares or 0.01% of its portfolio. Cowen Gp last reported 6,500 shares in the company. Wexford Capital Limited Partnership holds 0.19% or 30,516 shares in its portfolio. Cornerstone Incorporated last reported 0.01% of its portfolio in the stock. Stifel last reported 11,376 shares in the company. The Cayman Islands-based Cqs Cayman Ltd Partnership has invested 0.65% in Radius Health Inc (NASDAQ:RDUS). California State Teachers Retirement System accumulated 66,170 shares or 0.01% of the stock. Mutual Of America Capital Mngmt Lc, a New York-based fund reported 36,283 shares. Moreover, Wealthtrust has 0.01% invested in Radius Health Inc (NASDAQ:RDUS) for 350 shares. The Texas-based Next Finance Gp has invested 0% in Radius Health Inc (NASDAQ:RDUS). Farallon Cap Management Ltd Liability Co reported 1.54 million shares or 0.78% of all its holdings. Profund Advisors Lc holds 0.03% or 19,156 shares in its portfolio. Bb Biotech Ag has invested 6.33% of its portfolio in Radius Health Inc (NASDAQ:RDUS). The New York-based Jennison Associates Lc has invested 0.04% in Radius Health Inc (NASDAQ:RDUS). Tourbillon Cap Prtn Ltd Partnership, a New York-based fund reported 2.28M shares.

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The company has a market cap of $2.20 billion. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. It currently has negative earnings. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women.

RDUS Company Profile

Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.

More recent Radius Health Inc (NASDAQ:RDUS) news were published by: Fool.com which released: “Why Radius Health Inc. Dropped 45% in January” on February 08, 2016. Also Fool.com published the news titled: “Why Radius Health Inc. is Screaming Higher Today” on February 22, 2016. Philly.com‘s news article titled: “Radius Health eyes drug launch, expands in Wayne” with publication date: June 22, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment